Medtronic touts In.Pact Admiral DCB data

Medtronic (NYSE:MDT) today touted data from a pair of studies of its In.Pact Admiral drug-coated balloon, presented today at the annual Vascular Interventional Advances conference in Las Vegas. Researchers revealed the formal cost-effectiveness analysis of the U.S. cohort of Medtronic’s In.Pact SFA trial, and in-stent restenosis cohort data from its In.Pact Global study. Medtronic said the 2-year, prospective cost-effectiveness study of 181 patients showed that, although treatment with the drug-coated balloon was more expensive than with standard percutaneous transluminal angioplasty, costs were actually $100 lower over 2 years of follow-up, as the DCB-treated arm showed a significantly lower rate of target limb revascularization procedures. Index hospitalization costs with In.Pact Admiral were $8,293, compared with $7,164 for the PTA arm. That was offset by a reduction in follow-up costs for the DCB-treated group, at $2,984 over 2 years compared with $4,196 for the control group. “While the index hospitalization costs were approximately $1,100 per patient higher in patients treated with DCB compared to standard PTA, over the 2-year follow up period, treatment costs were approximately $1,200 per patient less with DCB than standard PTA,” presenter Dr. David Cohen, of Saint Luke’s Mid America Heart Institute in Kansas City, said in prepared remarks. “This net economic advantage for In.Pact Admiral DCB was driven primarily by the significant r...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Drug-Eluting Balloons Medtronic Peripheral Artery Disease Vascular Interventional Advances (VIVA) Source Type: news